黑麻利2型反应患者的疗效和安全研究
一项为期12周的开放标签,随机,护理标准控制的,剂量的安全性和功效研究,对中度至重度急性或复发性麻风病患者的多vramilast研究
Dovramilast has not been approved for leprosy type 2 reaction (erythema nodosum leprosum, ENL) or any other disease anywhere in the world. In this study, an experimental drug called dovramilast is being tested to see how it compares to current treatments for leprosy type 2 reaction. Specifically, this study aims to assess the efficacy of 100mg or 150 mg dovramilast compared with standard treatments (also known as standard of care). This study also aims to assess the safety of two strengths in adults with leprosy type 2 reaction.
研究概览
研究类型
注册 (估计的)
阶段
- 阶段2
联系人和位置
学习地点
-
-
-
Yogyakarta、印度尼西亚
- 招聘中
- Universitas Gadjah Mada
-
接触:
- Shinta Trilaksmi Dewi, MD, PhD
- 电话号码:+6282137381045
- 邮箱:shinta.trilaksmi.d@ugm.ac.id
-
-
-
-
-
Divo、科特迪瓦
- 尚未招聘
- Chr de Divo
-
-
-
-
Washington
-
Seattle、Washington、美国、98104
- 招聘中
- Harborview Medical Center, University of Washington
-
接触:
- Dr Jason Simmons, MD, PhD
- 电话号码:206-744-5463
- 邮箱:jasonds@uw.edu
-
-
-
-
-
Manila、菲律宾
- 招聘中
- Philippine General Hospital, University of the Philippines, Manila
-
接触:
- Dofitas
- 电话号码:63285548400
- 邮箱:bldofitas@up.edu.ph
-
-
-
-
-
Abomey-Calavi、贝宁
- 尚未招聘
- Centre de Dépistage de Traitement de la Lèpre et de l'Ulcère de Burulli
-
-
-
-
-
Tôlanaro、马达加斯加
- 招聘中
- Programme national lutte contre la lèpre
-
接触:
- Andrinamira Randrianantoandro, MD
- 电话号码:+261 340600115
- 邮箱:andriamiradomoina@gmail.com
-
-
参与标准
资格标准
适合学习的年龄
接受健康志愿者
有资格学习的性别
描述
Inclusion Criteria:
-
Aged 18 years of age or older.
-
Provision of written informed consent.
-
Laboratory confirmed previous or current Mycobacterium leprae or Mycobacterium lepromatosis infection.
-
Leprosy type 2 reaction meeting the following criteria:
-
Either:
i. Acute (first episode and no treatment initiated) or ii. Recurrent (at least one further episode occurring 28 days or more after withdrawal of leprosy type 2 reaction treatment).
-
Presence of at least 10 leprosy type 2 reaction tender papular and/or nodular skin lesions (not including scars).
-
An ENLIST score of at least 9.
-
-
If a woman of reproductive potential, agree to the use of two reliable contraceptive measures (at least one of which is a highly effective form of contraception) from Screening until at least 4 weeks after completion of treatment with dovramilast or standard of care. Refer to Special Considerations for additional information.
-
If male (including those who have had a successful vasectomy), agree to using a latex condom during any sexual contact with women of reproductive potential from Screening until at least 4 weeks after completion of treatment with dovramilast or standard of care.
Exclusion Criteria:
-
Chronic leprosy type 2 reaction, defined as the reaction occurring for 24 weeks or more during which a subject has required treatment either continuously or where any treatment free period had been < 28 days.
-
Receipt of thalidomide, lenalidomide, pomalidomide, systemic corticosteroids, clofazimine (> 50 mg/day), apremilast or any other phosphodiesterase (PDE) 4 inhibitor, or immunosuppressive/immunomodulatory treatment within 28 days of Baseline.
-
Receipt of an investigational agent within 28 days of Baseline or 5 half-lives of the investigational agent (whichever is longer).
-
Leprosy type 2 reaction with orchitis, uveitis, iritis, or severe neuritis (Grade 3 or greater severe neuritis).
-
Current diagnosis of leprosy type 1 reaction or Lucio's phenomenon.
-
Current tuberculosis, malaria, cutaneous or visceral leishmaniasis or other serious bacterial, viral, or parasitic infection at Screening or Baseline.
-
Active systemic fungal infection requiring or undergoing treatment.
-
Other than leprosy type 2 reaction, any clinically significant (as determined by the Investigator) cardiac, endocrinologic, pulmonary, neurologic, psychiatric, hepatic, renal, hematologic, immunologic disease, or other major disease that is currently uncontrolled.
-
Other than leprosy type 2 reaction, any other dermatological condition that could, in the opinion of the Investigator, interfere with the study assessments.
-
Chronic hepatitis B, chronic hepatitis C, or human immunodeficiency virus (HIV) positive.
-
Pregnant women or breastfeeding mothers.
-
Use (or planned use) of antimetabolites or alkylating agents, rifampin use more frequent than monthly, phenobarbital, carbamazepine, phenytoin, traditional or herbal preparations (including St. John's wort), foods (including grapefruit) known to affect activity of the cytochrome (CYP)3A4 enzyme; of all strong CYP3A and P-gp inhibitors including ketoconazole, itraconazole, voriconazole, posaconazole, clarithromycin, ritonavir, cobicistat, diltiazem; and sensitive substrates of CYP3A4, CYP2C9, CYP2C19, and P-gp. Other CYP3A4, CYP2C9, CYP2C19, and P-gp non-sensitive substrates should be used with caution when concomitantly administered with dovramilast.
-
Known or suspected active substance abuse or a history of substance abuse within 6 months prior to Screening.
-
Prior history of suicide attempt at any time in the subject's lifetime prior to Screening or Randomization, or major psychiatric illness requiring hospitalization within the last 3 years.
-
Current diagnosis of depression, and/or history of suicide ideation
-
History of or presence of cardiac disease, including:
- Clinically significant abnormal electrocardiogram
- QTcF > 450 msec
-
Receipt of a vaccination within 7 days of Baseline.
-
Known or suspected hypersensitivity to: PDE4 inhibitors including dovramilast or apremilast; thalidomide; prednisolone, or; excipients used in the formulation of dovramilast, thalidomide or prednisolone.
-
Body Mass Index < 15 kg/m^2 or > 35 kg/m^2.
-
Unable to, or significant difficulty with, swallowing tablets/capsules.
-
Anemia requiring transfusion.
-
History of or current pancreatitis.
-
Known or suspected cirrhosis of the liver.
-
The following laboratory abnormalities:
- White blood cells (WBC) < 2.5 x 10^9/ L.
- Neutrophils (granulocytes) < 1.0 x 10^9/L.
- Platelets < 80 x 10^9/L.
- Aspartate aminotransferase or alanine aminotransferase > 2 times the upper limit of reference range.
- Albumin < 30 mg/dL.
- Bilirubin > 2 mg/dL
- Calculated creatinine clearance (Cockcroft Gault) < 50 milliliter (mL)/minute.
- Lipase ≥ 1.6 times the upper limit
-
Previous participation in this study
-
Unwilling, unlikely or unable to comply with all protocol specified assessments, including photographic assessments
-
Enrolled in another leprosy type 2 reaction treatment study
学习计划
研究是如何设计的?
设计细节
- 主要用途:治疗
- 分配:随机化
- 介入模型:并行分配
- 屏蔽:无(打开标签)
武器和干预
参与者组/臂 |
干预/治疗 |
|---|---|
|
实验性的:多vramilast 100毫克
|
Dovramilast |
|
实验性的:多vramilast 150毫克
|
Dovramilast |
|
有源比较器:Standard of care
Prednisolone (or thalidomide US sites only) |
Standard of care Standard of care (US only) |
研究衡量的是什么?
主要结果指标
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
The proportion of dovramilast (100 mg or 150 mg) recipients achieving a 75% improvement in leprosy type 2 reaction skin lesions at week 12
大体时间:12 weeks
|
The proportion of subjects achieving a reduction of leprosy type 2 reaction skin lesion count of at least 75% from Baseline at Week 12 without the need for rescue. Rescue is defined as:
|
12 weeks
|
|
Incidence and severity of adverse events
大体时间:12 weeks
|
The incidence and severity of adverse events, changes in vital signs and blood dyscrasias |
12 weeks
|
次要结果测量
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
从基线入伍(红斑麻风病)的变化严重程度量表评分
大体时间:在每个基准时间点
|
在每个基准时间点
|
|
|
基线等级的神经病的变化
大体时间:12周
|
12周
|
|
|
需要救援药物的受试者的比例和启动救援药物的时间
大体时间:12周
|
12周
|
|
|
施用的麻风病的总治疗总量
大体时间:12周
|
12周
|
|
|
Resolution of fever to ≤ Grade 1
大体时间:12 weeks
|
Proportion of subjects with resolution of fever to ≤ Grade 1 among the subgroup of subjects with fever present at Baseline at Grade 2 or greater. |
12 weeks
|
|
Skin lesion count changes
大体时间:12 weeks
|
• Change from Baseline in skin lesion count up to and including Week 12. |
12 weeks
|
|
Change from Baseline of each of the following parameters when present at Baseline at Grade 2 or greater
大体时间:from baseline to Week 12
|
|
from baseline to Week 12
|
|
Time to resolution
大体时间:12 weeks
|
For each individual leprosy type 2 reaction when present at least Grade 1 at Baseline |
12 weeks
|
|
Recurrences
大体时间:48 weeks
|
Recurrence is defined as new signs and symptoms consistent with leprosy type 2 reaction. The number of Recurrence episodes requiring treatment. |
48 weeks
|
|
Exposure metrics of dovramilast
大体时间:48 weeks
|
Area under the curve (AUC) |
48 weeks
|
|
Exposure metrics of the dovramilast metabolite M15
大体时间:48 weeks
|
Area under the curve (AUC) |
48 weeks
|
|
Skin lesion count changes
大体时间:12 weeks
|
• Proportion of Responders at each post-Baseline timepoint. |
12 weeks
|
|
Skin lesion count changes
大体时间:12 weeks
|
Proportion of subjects achieving a reduction of leprosy type 2 reaction skin lesion count from Baseline of 50%, 90% and 100% without Rescue at Week 12. |
12 weeks
|
|
Exposure metrics of dovramilast
大体时间:48 weeks
|
Including AUC, Cmax, and Tmax. |
48 weeks
|
|
Exposure metrics of dovramilast
大体时间:48 weeks
|
Cmax |
48 weeks
|
|
Exposure metrics of dovramilast
大体时间:48 weeks
|
Tmax. |
48 weeks
|
其他结果措施
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
Quantification of immunological markers in whole blood samples by central laboratory, blinded to patient identification, treatment arm, and study visit
大体时间:48 weeks
|
Concentration of inflammatory cytokines |
48 weeks
|
|
Quantification of immunological markers in skin biopsies by central laboratory, blinded to patient identification, treatment arm, and study visit
大体时间:48 weeks
|
Leukocyte infiltration of skin lesions by histology |
48 weeks
|
合作者和调查者
研究记录日期
研究主要日期
学习开始 (实际的)
初级完成 (估计的)
研究完成 (估计的)
研究注册日期
首次提交
首先提交符合 QC 标准的
首次发布 (实际的)
研究记录更新
最后更新发布 (实际的)
上次提交的符合 QC 标准的更新
最后验证
更多信息
此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.